ARTICLE | Clinical News
EV06: Phase I/II data
May 16, 2016 7:00 AM UTC
Top-line data from a double-blind, U.S. Phase I/II trial in 75 patients ages 45-55 with presbyopia showed that twice-daily 1.5% topical EV06 ophthalmic solution met the primary endpoint of improving D...